
18F-DCFPyL PET/MRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer...
Prostate CancerThe purpose of this research study is to see if patients' tumor can be identified by 18F-DCFPyL PET/MRI scan. The radioactive study agent, 18FDCFPyL, combined with PET/MRI scan may be able to identify smaller tumors than the standard of care contrast-enhanced CT or MRI scan.

Pegcetacoplan Early Access Program for PNH
Paroxysmal Nocturnal Hemoglobinuria (PNH)This is an Early Access Program (EAP) which will provide access to pegcetacoplan for eligible participants with paroxysmal nocturnal hemoglobinuria (PNH).

Expanded Access for LOXO-260 in Participants With Cancer Caused by an Abnormal RET Gene That Did...
CarcinomaNon-Small-Cell Lung1 moreExpanded access for participants with cancer caused by an abnormal RET gene that did not respond/is no longer responding to treatment with a type of drug called a RET inhibitor. The treating physician/investigator contacts Loxo Oncology, Inc. when, based on their medical opinion, a patient meets the criteria for expanded access.

Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory...
Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)The EAP is for patients with relapsed/refractory diffuse large b-cell lymphoma (R/R DLBCL) that cannot be treated by currently available drugs, cell therapy, or clinical trials. ADC Therapeutics will evaluate patients for approval into the program.

An Intermediate Size Expanded Access Protocol of Elamipretide
Mitochondrial DiseasesBarth SyndromeChoosing to participate in an expanded access program is an important personal decision. Talk with your doctor to learn more about this program. The treating physician must contact StealthBiotherapeutics using the Expanded Access Program Contacts provided. Elamipretide will only be made available after careful review of an individual request submitted by the treating physician. The initiation and conduct of the treatment with elamipretide for an individual patient, and compliance with this treatment guideline, will be under the full and sole responsibility of the treating physician.

Expanded Access Use of L-MTP-PE for the Treatment of Osteosarcoma
OsteosarcomaThis expanded access protocol will allow access to treatment with L-MTP-PE for people with osteosarcoma. L-MTP-PE is an investigational drug that has not been approved by the FDA to treat any condition, including osteosarcoma. L-MTP-PE works by activating certain types of white blood cells, and these active white blood cells help the immune system kill cancer cells.

Sponsor Initiated Expanded Access Protocol, Intermediate-Size Patient Population
Ligneous ConjunctivitisThe purpose of this protocol is to provide compassionate use of Kedrion Human Plasminogen Ophthalmologic Drops to an expanded population of patients diagnosed with ligneous conjunctivitis associated with type I Plasminogen deficiency until product licensure, and/or until a new clinical trial is available and the patients in treatment under Expanded Access are eligible to participate in the new trial.

Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas...
GliomaH3 K27MThis is an intermediate-size expanded access protocol to provide ONC201 to patients with H3 K27M-mutant and/or midline gliomas who cannot access ONC201 through clinical trials.

Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19
COVID-19The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

MAP Treatment Plan With Afinitor for Postmenopausal Women With Advanced HR+ Breast Cancer
Advanced Hormone Receptor Positive (HR+) Breast CancerThe purpose of this Managed Access Program (MAP) Cohort Treatment Plan is to provide guidance to the Physician for the treatment and monitoring of patients in the Cohort MAP.